



Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

November 9, 2021

BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 9, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

- **Barclays Gene Editing & Gene Therapy Summit**
Date: Monday, November 15th at 10:30 a.m. Eastern Time
- **Stifel 2021 Virtual Healthcare Conference**
Date: Monday, November 15th at 3:20 p.m. Eastern Time
- **Jefferies London Healthcare Conference**
Date: Tuesday, November 16th at 8:40 a.m. Eastern Time

For presentations and fireside chats that are webcast live, an access link will be available on the Sangamo Therapeutics website in the Investors and Media section under [Events and Presentations](#). The presentations will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don't exist. For more information about Sangamo, visit www.sangamo.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211109005592/en/): <https://www.businesswire.com/news/home/20211109005592/en/>

Investor Relations & Media Inquiries
Aron Feingold
628.252.7494
afeingold@sangamo.com

Source: Sangamo Therapeutics, Inc.